Skip Navigation


Biostatistics Advance Access originally published online on November 11, 2005
Biostatistics 2006 7(2):268-285; doi:10.1093/biostatistics/kxj006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary material
Right arrowOA All Versions of this Article:
7/2/268    most recent
kxj006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Segal, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segal, M. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.

Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited

Mark R. Segal

Division of Biostatistics, University of California, San Francisco, CA 94143-0560, USA mark{at}biostat.ucsf.edu

Diffuse large-B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes and is the most common type of lymphoma in adults. While treatment advances have been substantial in what was formerly a fatal disease, less than 50% of patients achieve lasting remission. In an effort to predict treatment success and explain disease heterogeneity clinical features have been employed for prognostic purposes, but have yielded only modest predictive performance. This has spawned a series of high-profile microarray-based gene expression studies of DLBCL, in the hope that molecular-level information could be used to refine prognosis. The intent of this paper is to reevaluate these microarray-based prognostic assessments, and extend the statistical methodology that has been used in this context. Methodological challenges arise in using patients' gene expression profiles to predict survival endpoints on account of the large number of genes and their complex interdependence. We initially focus on the Lymphochip data and analysis of Rosenwald et al. (2002). After describing relationships between the analyses performed and gene harvesting (Hastie et al., 2001a), we argue for the utility of penalized approaches, in particular least angle regression-least absolute shrinkage and selection operator (Efron et al., 2004). While these techniques have been extended to the proportional hazards/partial likelihood framework, the resultant algorithms are computationally burdensome. We develop residual-based approximations that eliminate this burden yet perform similarly. Comparisons of predictive accuracy across both methods and studies are effected using time-dependent receiver operating characteristic curves. These indicate that gene expression data, in turn, only delivers modest predictions of posttherapy DLBCL survival. We conclude by outlining possibilities for further work.

Keywords: Diffuse large-B-cell lymphoma; Gene harvesting; Least angle regression; Microarray; Proportional hazards; Time-dependent ROC curve


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BioinformaticsHome page
I. Sohn, J. Kim, S.-H. Jung, and C. Park
Gradient lasso for Cox proportional hazards model
Bioinformatics, July 15, 2009; 25(14): 1775 - 1781.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Simon
The Use of Genomics in Clinical Trial Design
Clin. Cancer Res., October 1, 2008; 14(19): 5984 - 5993.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. J. Raz, M. R. Ray, J. Y. Kim, B. He, M. Taron, M. Skrzypski, M. Segal, D. R. Gandara, R. Rosell, and D. M. Jablons
A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma
Clin. Cancer Res., September 1, 2008; 14(17): 5565 - 5570.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
H.M. Bovelstad, S. Nygard, H.L. Storvold, M. Aldrin, O. Borgan, A. Frigessi, and O.C. Lingjaerde
Predicting survival from microarray data a comparative study
Bioinformatics, August 15, 2007; 23(16): 2080 - 2087.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
M. Schumacher, H. Binder, and T. Gerds
Assessment of survival prediction models based on microarray data
Bioinformatics, July 15, 2007; 23(14): 1768 - 1774.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert
Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome
Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.